Literature DB >> 10632362

Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines.

A S Pearson1, P E Koch, N Atkinson, M Xiong, R W Finberg, J A Roth, B Fang.   

Abstract

Adenoviral vectors are a widely used means of gene transfer. However, transgene expression after adenoviral administration varies among different carcinoma cell lines. We hypothesized that this variation is attributable, in part, to the presence of cell surface molecules involved in adenoviral infection. To test this, we first assessed adenovirus-mediated transgene expression in four human lung carcinoma cell lines and four human pancreatic carcinoma cell lines in terms of luciferase activities and found it to vary from 4.8 x 10(4) to 6.1 x 10(7) relative light units/microg of protein. Then, to determine whether the molecules involved in the entry of adenovirus into host cells were responsible for this variation, we evaluated the expression of alpha(v)beta5, alpha(v), beta3, alpha5, and beta1 integrins and that of coxsackievirus and adenovirus receptor (CAR) in these cell lines. Statistical analysis revealed that the levels of beta3 were associated with the levels of transgene expression. Blocking analysis showed that adenovirus-mediated gene transfer could be blocked by antibodies against these six molecules but not by the antibodies against alpha2 or alpha3 integrins, thus suggesting that the integrins alphavbeta5, alpha(v), beta3, alpha5, and beta1 and CAR molecules could limit adenovirus-mediated gene transfer when their levels fell below a certain threshold. Furthermore, cells expressing low levels of beta3 and resistant to conventional adenoviral vectors were susceptible to a vector containing the heparin-binding domain in its fiber, thus suggesting that redirecting vectors to receptors other than CAR may bypass the integrin pathway. These findings may have implications for improving the efficiency of adenovirus-mediated gene transfer and developing novel adenoviral vectors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632362

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Analysis of the expression of coxsackievirus and adenovirus receptor in five colon cancer cell lines.

Authors:  Yassan Abdolazimi; Majid Mojarrad; Mehrdad Pedram; Mohammad Hossein Modarressi
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

3.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

4.  5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes.

Authors:  Chiara Cabrele; Mandy Vogel; Pompiliu Piso; Markus Rentsch; Josef Schröder; Karl W Jauch; Hans J Schlitt; Alexander Beham
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

Review 5.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

6.  Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach.

Authors:  Siddik Sarkar; Bridget A Quinn; Xuening Shen; Paul Dent; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  Mol Pharmacol       Date:  2014-12-01       Impact factor: 4.436

7.  Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.

Authors:  Dietmar Jacob; Guido Schumacher; Marcus Bahra; John Davis; Hong-Bo Zhu; Li-Dong Zhang; Fuminori Teraishi; Peter Neuhaus; Bing-Liang Fang
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

8.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.

Authors:  Xiaochun Zhang; Ritsuko Komaki; Li Wang; Bingliang Fang; Joe Y Chang
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens.

Authors:  Christianne J Buskens; Willem A Marsman; John G Wesseling; G Johan A Offerhaus; Masato Yamamoto; David T Curiel; Piter J Bosma; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.